Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU). CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. As previously presented, CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, indicative of systemic mast cell ablation in a Phase 1a single dose, healthy volunteer study.

Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria

Why Celldex Has Been A Big Winner In 2020

Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Celldex Therapeutics (CLDX) Stock?

HAMPTON, N.J., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global Healthcare Conference and the HC Wainwright & CO 22nd Annual Global Investment Virtual Conference. Presentation details are as follows:

Celldex Therapeutics to Present at Upcoming Healthcare Conferences

Aileron Therapeutics

Emergent BioSolutions

Horizon Pharma

Novavax

Here we discuss five biotech companies recording impressive growth so far in 2020.

5 Biotech Stocks Up More Than 100% This Year So Far

HAMPTON, N.J., Aug.  24, 2020  (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients with advanced or metastatic solid tumors that have progressed during or after standard of care therapy. CDX-527 is the first candidate from Celldex’s bispecific antibody platform. It uses Celldex’s proprietary highly active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation, while preventing PD-1 inhibitory signals that subvert the immune response.

Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors

Celldex Therapeutics' (CLDX) CEO Anthony Marucci on Q2 2020 Results - Earnings Call Transcript

--Conference Call and Webcast today at 4:30pm ET-- --Conference Call and Webcast today at 4:30pm ET--

Celldex Provides Corporate Update and Reports Second Quarter 2020 Results

HAMPTON, N.J., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter  financial results and to provide an update on key research and development and business objectives for the remainder of 2020.

Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

As of late, it has definitely been a great time to be an investor in Celldex Therapeutics, Inc. (CLDX).

Celldex Therapeutics, Inc. (CLDX) Shares March Higher, Can It Continue?

Ideaya Biosciences Inc

QuidelOrtho Corp

Here's what pushed up shares of the highest-flying healthcare stocks.

3 Healthcare Stocks That Surged Last Week

The market is reacting to large stock purchases from inside and outside the company.

Here's Why Celldex Therapeutics Stock Is Soaring Today

HAMPTON, N.J., June  18, 2020  (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614 shares (including 2,006,688 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares) of its common stock, par value $0.001 per share.

Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

HAMPTON, N.J., June  15, 2020  (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public offering. Celldex is offering 13,377,926 shares of its common stock, par value $0.001 per share, at a price to the public of $9.75 per share. In connection with the offering, Celldex has also granted the underwriter a 30-day option to purchase up to an additional 2,006,688 shares of common stock offered in the public offering, at the same public offering price per share less underwriting discounts and commissions.

Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock

Celldex Jumps On CDX-0159 Data

Celldex Therapeutics Inc (NASDAQ:CLDX) was trading 3% higher from the previous closing price.

Insider Buys Celldex Therapeutics's Stock

Shares of Celldex Therapeutics Inc (NASDAQ:CLDX) moved higher by 1.5% from the previous closing price.

Insider Buys Celldex Therapeutics' Shares

Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options

--Data strongly support expanding development into mast cell driven diseases----Data presented in a late-breaking session at EAACI Annual Congress 2020-- HAMPTON, N.J., June  06, 2020  (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced results from the Company’s Phase 1 randomized, double-blind, placebo-controlled, dose escalation study of KIT inhibitor CDX-0159 in healthy subjects. Data (presentation #1829) were featured in a late breaking presentation today at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020.

Celldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile

Is  (CLDX) Outperforming Other Medical Stocks This Year?

Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?

Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Celldex (CLDX) Soars: Stock Adds 10% in Session

Celldex also eligible to receive future milestone payments plus royalties Celldex also eligible to receive future milestone payments plus royalties

Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program

Celldex (CLDX) reported earnings 30 days ago. What's next for the stock?

Celldex (CLDX) Down 3.9% Since Last Earnings Report: Can It Rebound?

CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study

News for Celldex Therapeutics Stock (CLDX)